BluNADBooster Enhances Healthy Aging Biomarkers

Introduction to NAD+ and Healthy Aging

New groundbreaking research reveals that supplementation with BluNADBooster both increases and preserves nicotinamide adenine dinucleotide (NAD⁺) levels, significantly improving biomarkers associated with healthy aging.¹ This innovative herbal blend from NXT USA represents a paradigm shift in how the nutraceutical industry approaches age-related NAD+ decline.

The proprietary formulation combines standardized extracts of Punica granatum (pomegranate) and Tagetes erecta (marigold), offering what researchers describe as a dual-action approach to supporting optimal NAD+ metabolism. According to a December 9 press release from NXT USA, this botanical strategy addresses both the synthesis and preservation of NAD+ levels simultaneously.² The ingredient stands out in the marketplace for its exceptionally high polyphenol content, which contributes to its multifaceted health benefits.

Understanding BluNADBooster’s Dual-Action Mechanism

Why NAD+ Matters for Longevity

As humans age, NAD⁺ levels naturally decline, contributing to mitochondrial dysfunction, increased inflammation, and deterioration in both cognitive and physical performance. This age-related depletion is driven significantly by increased activity of cluster of differentiation 38 (CD38), an enzyme that degrades NAD+. Understanding this mechanism has become crucial for developing effective anti-aging interventions.

The Role of Plant-Derived Compounds

Scientific interest continues growing for plant-derived compounds capable of modulating NAD⁺ metabolism, as these botanical solutions offer potentially safer and more sustainable alternatives to synthetic precursors. Pomegranate (Punica granatum) contains abundant polyphenols that deliver powerful antioxidant, anti-inflammatory, and anti-aging properties. Meanwhile, marigold (Tagetes erecta) has demonstrated impressive hepatoprotective, neuroprotective, and ocular health benefits in previous scientific investigations.

Clinical Trial Design and Methodology

Study Parameters and Population

The randomized, double-blind, placebo-controlled clinical trial, titled “Comparative efficacy of a standardized herbal composition LN22199, nicotinamide riboside, and their combination on NAD+ metabolism in healthy aging adults,” was published in the Journal of Functional Foods in December 2025.

This comprehensive investigation enrolled 140 healthy aging adults who were randomly assigned to one of four treatment groups for a 60-day intervention period. The study compared BluNADBooster (designated as LN22199 in research protocols) against nicotinamide riboside (NR), a well-established NAD+ precursor, as well as examining a combination approach.

Treatment Groups and Dosing

Participants received one of the following daily regimens:

• 1000 mg of LN22199 (BluNADBooster alone)
• 500 mg of NR (nicotinamide riboside alone)
• Combination therapy: 500 mg of LN22199 plus 500 mg of NR
• Placebo (control group)

Primary Outcomes and Biomarker Measurements

Comprehensive Assessment Approach

Researchers evaluated multiple dimensions of health and aging, including:

• Blood NAD+ concentration levels
• CD38 enzymatic activity
• Inflammatory biomarkers
• Cognitive function assessments
• Physical performance metrics
• Quality-of-life measurements

This multifaceted approach provided robust evidence for BluNADBooster’s impact across various hallmarks of healthy aging.

Key Results: NAD+ Enhancement and CD38 Reduction

Impressive NAD+ Metabolism Support

LN22199 supplementation demonstrated remarkable effectiveness in supporting increases in NAD+ metabolism while simultaneously enhancing both cognitive and physical functions. The botanical blend achieved these benefits while reducing CD38 activity and systemic inflammation.

Quantified Clinical Outcomes

The study revealed several statistically significant improvements:

• Blood NAD⁺ levels increased by 26.48% with LN22199 supplementation alone
• CD38 activity decreased by 17.98% in the LN22199-only group
• Serum growth/differentiation factor 15 (GDF-15) reduced by 15.07% with BluNADBooster treatment

These findings strongly supported preclinical research data that had previously suggested LN22199 synergistically promotes NAD+ biosynthesis while simultaneously reducing CD38-mediated degradation. The researchers concluded: “These findings support a dual-action strategy of boosting NAD+ biosynthesis and limiting its degradation as a promising approach to mitigate advancing age-associated decline.”

Comprehensive Intervention Strategy

The study authors noted that “LN22199, when used alone or in combination with NR, provides a comprehensive intervention strategy that emerges as a safe and effective nutraceutical approach to promote healthy aging and mitochondrial function.”

Safety Profile and Tolerability

All treatment protocols were described as well tolerated throughout the 60-day study period. Notably, no serious adverse effects were reported among any participant groups, supporting BluNADBooster’s favorable safety profile for long-term supplementation in aging populations.

Clinical Implications for Aging Adults

Next-Generation NAD+ Support

Blue Helix and NXT USA developed this synergistic botanical blend specifically based on the complementary mechanisms of its constituent extracts. Eric Anderson, managing director at NXT USA and CEO of Blue Helix Health, emphasized the innovation: “The market has been waiting for an NAD⁺ solution that goes beyond precursors alone. BluNADBooster represents a next-generation approach—one that strengthens the body’s ability to generate and maintain healthy NAD⁺ levels while addressing the underlying mechanisms that cause NAD⁺ to decline with age.”

The Polyphenol Advantage

Anderson further explained: “This study confirms what we’ve believed for years: polyphenols matter, and they work in ways synthetic precursors cannot.” This distinction highlights BluNADBooster’s unique position in the NAD+ supplementation marketplace.

Future of NAD+ Supplementation

Multidimensional Scientific Validation

The clinical evidence and robust safety profile firmly support BluNADBooster’s application for promoting healthy aging benefits. Anderson emphasized the comprehensiveness of the research: “This is comprehensive, multidimensional evidence—science layered on science—to ensure the formulation truly delivers.”

Rapid, Measurable Benefits

Perhaps most remarkably, the study documented clinically validated improvements across multiple aging biomarkers within just 60 days. “For the first time, we’re seeing a clinically validated botanical strategy that supports multiple hallmarks of aging—including mitochondrial efficiency, inflammation, and cognitive resilience—within just 60 days,” Anderson concluded.

This breakthrough research establishes BluNADBooster as a scientifically validated option for individuals seeking evidence-based nutritional support for healthy aging and optimal NAD+ metabolism.